DK1361881T3 - Steroide hormonprodukter og fremgangsmåder til fremstilling heraf - Google Patents

Steroide hormonprodukter og fremgangsmåder til fremstilling heraf

Info

Publication number
DK1361881T3
DK1361881T3 DK01996273T DK01996273T DK1361881T3 DK 1361881 T3 DK1361881 T3 DK 1361881T3 DK 01996273 T DK01996273 T DK 01996273T DK 01996273 T DK01996273 T DK 01996273T DK 1361881 T3 DK1361881 T3 DK 1361881T3
Authority
DK
Denmark
Prior art keywords
products
methods
hormone
excipient
preparation
Prior art date
Application number
DK01996273T
Other languages
English (en)
Inventor
Thomas Schultz
Bradley A Clark
Angela Falzone
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1361881T3 publication Critical patent/DK1361881T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
DK01996273T 2000-12-14 2001-12-13 Steroide hormonprodukter og fremgangsmåder til fremstilling heraf DK1361881T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25566900P 2000-12-14 2000-12-14

Publications (1)

Publication Number Publication Date
DK1361881T3 true DK1361881T3 (da) 2006-02-20

Family

ID=22969374

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05076805T DK1591121T3 (da) 2000-12-14 2001-12-13 Fremgangsmåde til fremstilling af steroidhormonprodukter indeholdende et stabiliseringsmiddel i ikke-krystallinsk form
DK01996273T DK1361881T3 (da) 2000-12-14 2001-12-13 Steroide hormonprodukter og fremgangsmåder til fremstilling heraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05076805T DK1591121T3 (da) 2000-12-14 2001-12-13 Fremgangsmåde til fremstilling af steroidhormonprodukter indeholdende et stabiliseringsmiddel i ikke-krystallinsk form

Country Status (31)

Country Link
US (4) US7867990B2 (da)
EP (2) EP1591121B1 (da)
KR (1) KR100899032B1 (da)
CN (1) CN1290507C (da)
AT (2) ATE434439T1 (da)
AU (2) AU2002227421B2 (da)
BG (1) BG66178B1 (da)
BR (1) BRPI0116793B8 (da)
CA (1) CA2431521E (da)
CR (1) CR7022A (da)
CY (1) CY1109404T1 (da)
CZ (1) CZ306435B6 (da)
DE (2) DE60114467T2 (da)
DK (2) DK1591121T3 (da)
EC (1) ECSP034654A (da)
EE (1) EE05358B1 (da)
ES (2) ES2253451T3 (da)
HK (2) HK1057174A1 (da)
HU (1) HU230400B1 (da)
IL (2) IL156423A0 (da)
ME (1) ME00339B (da)
MX (1) MXPA03005339A (da)
NO (2) NO334341B1 (da)
NZ (1) NZ526517A (da)
PT (1) PT1591121E (da)
RS (1) RS50414B (da)
RU (1) RU2286155C2 (da)
SK (1) SK288222B6 (da)
UA (1) UA77404C2 (da)
WO (1) WO2002047693A2 (da)
ZA (1) ZA200305342B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
CZ306435B6 (cs) * 2000-12-14 2017-01-25 Ortho-Mcneil Pharmaceutical, Inc. Steroidní hormonální přípravek a způsob jeho přípravy
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
EP1820494B1 (en) * 2003-06-13 2010-01-13 Skendi Finance, Ltd. Microparticles consisting of estradiol and cholesterol
TWI547431B (zh) 2004-06-09 2016-09-01 史密斯克萊美占公司 生產藥物之裝置及方法
US8101244B2 (en) 2004-06-09 2012-01-24 Smithkline Beecham Corporation Apparatus and method for producing or processing a product or sample
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
WO2009100258A1 (en) * 2008-02-05 2009-08-13 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical solid state forms
AU2009231589B2 (en) 2008-04-03 2013-11-07 Neurmedix, Inc. Solid state forms of a pharmaceutical
EP2172190A1 (en) * 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US10231976B2 (en) * 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer
US10993879B2 (en) 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
CN102793929B (zh) * 2012-09-07 2013-12-11 上海奥科达生物医药科技有限公司 一种制备稳定非晶态药物制剂的方法
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US20200129438A1 (en) * 2018-10-31 2020-04-30 Edenbridge Pharmaceuticals, LLC Finished pharmaceutical dosage form comprising a low dose/high potency active pharmaceutical ingredient and one or more excipients
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2648700A (en) * 1946-11-02 1953-08-11 Searle & Co 2-methyl-2,7-dihydroxy-octahydrophenanthrene-1-propionic acid and derivatives thereof
US2636042A (en) * 1949-07-08 1953-04-21 S B Penick And Company Water-soluble hormone compounds
US2642427A (en) * 1951-08-01 1953-06-16 Abbott Lab Piperazine salts of cyclopentanopolyhydrophenanthrene-3-monosulfates
US2666066A (en) * 1951-09-28 1954-01-12 Abbott Lab Ethylenediamine salts of cyclopen-tanopolyhydrophenanthrene-3-monosulfates
US3032469A (en) * 1958-05-02 1962-05-01 Charles E Frosst & Company Long acting steroid compounds
US3568828A (en) * 1967-03-01 1971-03-09 Squibb & Sons Inc Modified sequential oral contraceptive
US3691212A (en) * 1970-04-24 1972-09-12 British Drug Houses Ltd 17alpha-(1',3'-alkadiynyl)-17beta-acyloxy(17beta-aroyloxy) steroids
US4046874A (en) * 1974-02-13 1977-09-06 Mead Johnson & Company Soapless shave composition
US4511551A (en) * 1982-11-18 1985-04-16 Unique Technologies, Incorporated Method and composition for the detection of a precancerous or leukemic condition in mammals
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4785103A (en) * 1985-03-07 1988-11-15 Teikoku Hormone Mfg. Co., Ltd. 2-oxa- or -aza-pregnane compounds
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
US5344392A (en) * 1990-09-28 1994-09-06 Baxter International Inc. Method and apparatus for preparation of solutions from concentrates
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
DE69207863T2 (de) * 1991-11-13 1996-06-05 Glaxo Canada Vorrichtung zur kontrollierten Wirkstoffreigabe
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
DE4229820C2 (de) * 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
IT1270831B (it) * 1993-09-17 1997-05-13 Romano Deghenghi Composizioni farmaceutiche orali effervescenti contenenti estrone
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
AR004178A1 (es) 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
BR9710566A (pt) * 1996-07-26 1999-08-17 American Home Prod M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
AU3567699A (en) * 1998-04-17 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6667050B1 (en) * 1999-04-06 2003-12-23 Galen (Chemicals) Limited Chewable oral contraceptive
CZ306435B6 (cs) * 2000-12-14 2017-01-25 Ortho-Mcneil Pharmaceutical, Inc. Steroidní hormonální přípravek a způsob jeho přípravy

Also Published As

Publication number Publication date
EP1361881B1 (en) 2005-10-26
BG66178B1 (bg) 2011-11-30
RU2003121240A (ru) 2005-02-10
YU47903A (sh) 2006-08-17
ES2253451T3 (es) 2006-06-01
UA77404C2 (en) 2006-12-15
PT1591121E (pt) 2009-07-20
BG107958A (bg) 2004-11-30
CN1290507C (zh) 2006-12-20
DE60114467D1 (de) 2005-12-01
WO2002047693A2 (en) 2002-06-20
CA2431521C (en) 2010-03-16
CA2431521A1 (en) 2002-06-20
CY1109404T1 (el) 2014-07-02
ZA200305342B (en) 2004-10-11
ECSP034654A (es) 2003-07-25
KR100899032B1 (ko) 2009-05-21
EP1361881A2 (en) 2003-11-19
AU2742102A (en) 2002-06-24
HUP0400646A2 (hu) 2004-06-28
WO2002047693A3 (en) 2002-11-07
NZ526517A (en) 2005-09-30
CN1489468A (zh) 2004-04-14
ATE434439T1 (de) 2009-07-15
ES2327538T3 (es) 2009-10-30
RS50414B (sr) 2009-12-31
NO334341B1 (no) 2014-02-10
BRPI0116793B8 (pt) 2021-05-25
BR0116793A (pt) 2004-01-27
DE60139087D1 (de) 2009-08-06
HUP0400646A3 (en) 2012-08-28
BRPI0116793B1 (pt) 2015-06-23
DK1591121T3 (da) 2009-10-05
US20140309204A1 (en) 2014-10-16
AU2002227421B2 (en) 2007-08-23
US7867990B2 (en) 2011-01-11
MXPA03005339A (es) 2004-03-26
SK8802003A3 (en) 2004-04-06
EE200300229A (et) 2003-08-15
RU2286155C2 (ru) 2006-10-27
MEP48808A (en) 2011-02-10
CZ306435B6 (cs) 2017-01-25
HK1057174A1 (en) 2004-03-19
EP1591121B1 (en) 2009-06-24
KR20030061856A (ko) 2003-07-22
IL156423A (en) 2010-04-29
HK1083457A1 (en) 2006-07-07
NO20032708D0 (no) 2003-06-13
CR7022A (es) 2009-02-23
IL156423A0 (en) 2004-01-04
US20110046099A1 (en) 2011-02-24
NO20131334L (no) 2003-07-04
EP1591121A1 (en) 2005-11-02
CA2431521E (en) 2013-04-16
US20020173669A1 (en) 2002-11-21
HU230400B1 (hu) 2016-04-28
NO20032708L (no) 2003-07-04
CZ20031896A3 (en) 2004-03-17
SK288222B6 (sk) 2014-09-04
EE05358B1 (et) 2010-12-15
US20110046095A1 (en) 2011-02-24
ME00339B (me) 2011-05-10
DE60114467T2 (de) 2006-07-20
ATE307591T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
DK1361881T3 (da) Steroide hormonprodukter og fremgangsmåder til fremstilling heraf
NO20062945L (no) Forlenget anvendelseskombinasjon omfattende ostrogener og progestiner
EP2433951A3 (en) A process for the preparation of drospirenone
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
TW200605880A (en) Progesterone receptor antagonist contraceptive regimens and kits
BRPI0513141A (pt) composição para anel vaginal, e, processo de contracepção a longo prazo
KR960704553A (ko) 적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen)
ZA200203439B (en) Novel tropical oestroprogestational compositions with systemic effect.
MY129798A (en) Process for preparing a pharmaceutical composition
WO2006023496A3 (en) Vaginal cream compositions, kits thereof and methods of using thereof
MX2010004353A (es) Combinación anticonceptiva oral entiemética.
TW200716137A (en) Tanaproget compositions containing ethinyl estradiol
WO2004110408A3 (en) Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
HK1084015A1 (en) Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2-
WO2005092441A3 (en) Extended cycle multiphasic oral contraceptive method
HUP0300626A3 (en) Use of progestogen and mifepristone for preparation of anticancer pharmaceutical compositions
MD3536G2 (ro) Amestec uscat pentru tencuire pe bază de ciment
PE20091020A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa